RxDoctor Payments Data

Wilburn Furniss, MD

Family Medicine · Nacogdoches, TXNPI 1932398377

Payments from drug & device makers

$1,780in general payments, 2019–2025

Across 125 payments — averaging $14.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$741
  • Merck$303
  • Bayer$221
  • Lilly USA, LLC$160
  • Genentech USA, Inc.$117
  • AstraZeneca$65
  • plus $174 from 8 others

What the payments were for

  • Food & beverage$1,73597%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,780 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$292,057
Medicare patients
485
Services billed
5,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$68,659
MounjaroTirzepatide48$55,191
OzempicSemaglutide37$47,991
JardianceEmpagliflozin26$19,140
Repatha SureclickEvolocumab15$11,113
FarxigaDapagliflozin Propanediol12$10,756
ArexvyRsvpref3 Antigen/As01e/Pf31$9,839
Tresiba Flextouch U-200Insulin Degludec15$6,567
ShingrixVaricella-Zoster Ge/As01b/Pf25$5,650
Tresiba Flextouch U-100Insulin Degludec13$2,857
Fentanyl24$2,474
Lisdexamfetamine Dimesylate11$2,452
Rosuvastatin Calcium113$1,510
Nano 2nd Gen Pen NeedlePen Needle, Diabetic15$1,475
Boostrix TdapDiphth,pertuss(Acell),tet Vac20$1,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$68,65987 claims
Lilly USA, LLCMounjaro$160$55,19148 claims
Novo NordiskOzempic$741$47,99137 claims
Boehringer IngelheimJardiance$11$19,14026 claims
GSKArexvy, Shingrix$15$15,48956 claims
AstraZenecaFarxiga$65$10,75612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Nacogdoches

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →